See more : Rotor Acquisition Corp. (ROT) Income Statement Analysis – Financial Results
Complete financial analysis of NanoViricides, Inc. (NNVC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NanoViricides, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Beijing Labtech Instruments Co., Ltd. (688056.SS) Income Statement Analysis – Financial Results
- J.S. Corrugating Machinery Co., Ltd. (000821.SZ) Income Statement Analysis – Financial Results
- M/I Homes, Inc. (MHO) Income Statement Analysis – Financial Results
- JustSystems Corporation (4686.T) Income Statement Analysis – Financial Results
- Beijing Hualian Department Store Co., Ltd (000882.SZ) Income Statement Analysis – Financial Results
NanoViricides, Inc. (NNVC)
About NanoViricides, Inc.
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 759.01K | 747.53K | 723.33K | 704.54K | 699.72K | 695.91K | 680.06K | 662.95K | 659.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -759.01K | -747.53K | -723.33K | -704.54K | -699.72K | -695.91K | -680.06K | -662.95K | -659.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.44M | 6.39M | 5.78M | 6.11M | 4.70M | 5.92M | 4.83M | 5.53M | 5.03M | 3.66M | 5.13M | 4.29M | 4.27M | 4.16M | 3.20M | 1.73M | 839.24K | 731.81K | 899.89K | 30.77K |
| General & Administrative | 3.08M | 2.55M | 2.33M | 2.63M | 3.30M | 2.74M | 4.50M | 4.07M | 3.83M | 3.40M | 3.54M | 2.30M | 1.82M | 2.27M | 1.74M | 1.09M | 1.95M | 2.35M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.08M | 2.55M | 2.33M | 2.63M | 3.30M | 2.74M | 4.50M | 4.07M | 3.83M | 3.40M | 3.54M | 2.30M | 1.82M | 2.27M | 1.74M | 1.09M | 1.95M | 2.35M | 1.70M | 35.23K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -142.67K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.52M | 8.94M | 8.11M | 8.74M | 8.00M | 8.66M | 9.33M | 9.60M | 8.86M | 7.06M | 8.67M | 6.59M | 6.08M | 6.43M | 4.94M | 2.82M | 2.79M | 3.08M | 2.60M | 66.01K |
| Cost & Expenses | 8.52M | 8.94M | 8.11M | 8.74M | 8.00M | 8.66M | 9.33M | 9.60M | 8.86M | 7.06M | 8.67M | 6.59M | 6.08M | 6.43M | 4.94M | 2.82M | 2.79M | 3.08M | 2.60M | 66.01K |
| Interest Income | 221.97K | 355.83K | 11.86K | 9.35K | 17.08K | 55.50K | 100.43K | 60.96K | 62.64K | 160.86K | 171.00K | 55.59K | 46.79K | 14.34K | 0.00 | 31.93K | 0.00 | 54.51K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 938.00 | 5.12K | 85.41K | 93.67K | 0.00 | 544.49K | 2.13M | 2.47M | 3.82M | 3.66M | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 90.56K | 0.00 | 0.00 |
| Depreciation & Amortization | 759.01K | 747.53K | 723.33K | 704.54K | 699.72K | 695.91K | 680.06K | 662.95K | 659.55K | 302.74K | 212.01K | 219.65K | 219.65K | 527.74K | 90.29K | 12.29K | 13.47K | 36.30K | 44.56K | 0.00 |
| EBITDA | -7.76M | -7.84M | -7.38M | -8.03M | -7.30M | -7.96M | -8.59M | -8.94M | -8.20M | -6.76M | -8.46M | -7.56M | -5.99M | -5.95M | -4.65M | -2.83M | -2.73M | -3.03M | -2.55M | -66.01K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.52M | -8.94M | -8.11M | -8.74M | -8.00M | -8.66M | -9.33M | -9.60M | -8.86M | -7.06M | -8.67M | -6.59M | -6.08M | -6.43M | -4.94M | -2.82M | -2.79M | -3.08M | -2.60M | -66.01K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 221.97K | 354.90K | 6.74K | -78.08K | -5.45M | 235.24K | 761.71K | -703.77K | -1.87M | 4.86M | -4.93M | -2.29M | -125.46K | -47.71K | 358.27K | -26.20K | 53.70K | -36.05K | -688.58K | 0.00 |
| Income Before Tax | -8.29M | -8.59M | -8.11M | -8.82M | -13.45M | -8.42M | -8.56M | -10.30M | -10.72M | -2.20M | -14.11M | -8.88M | -6.21M | -6.48M | -4.74M | -2,787.80B | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 355.83K | -6.74K | 85.41K | -49.00K | -179.75K | 1.31M | 2.13M | 2.47M | 3.82M | 3.66M | 1.09M | 125.46K | 47.71K | -195.74K | 31.93B | -53.70K | 36.05K | 688.58K | 66.01K |
| Net Income | -8.29M | -8.59M | -8.10M | -8.91M | -13.40M | -8.24M | -8.56M | -10.30M | -10.72M | -2.20M | -14.11M | -8.88M | -6.21M | -6.48M | -4.74M | -2.79M | -2.74M | -3.12M | -3.28M | -66.01K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.70 | -0.74 | -0.70 | -0.82 | -2.39 | -2.30 | -2.64 | -3.43 | -3.72 | -0.78 | -5.51 | -3.87 | -2.90 | -3.26 | -2.54 | -1.63 | -1.64 | -1.94 | -2.22 | -0.05 |
| EPS Diluted | -0.70 | -0.74 | -0.70 | -0.82 | -2.39 | -2.30 | -2.64 | -3.43 | -3.72 | -0.74 | -5.51 | -3.73 | -2.90 | -3.26 | -2.54 | -1.63 | -1.64 | -1.94 | -2.22 | -0.05 |
| Weighted Avg Shares Out | 11.87M | 11.63M | 11.53M | 10.90M | 5.62M | 3.59M | 3.25M | 3.01M | 2.88M | 2.83M | 2.56M | 2.29M | 2.14M | 1.99M | 1.86M | 1.71M | 1.67M | 1.60M | 1.48M | 1.43M |
| Weighted Avg Shares Out (Dil) | 11.87M | 11.63M | 11.53M | 10.90M | 5.62M | 3.59M | 3.25M | 3.01M | 2.88M | 2.96M | 2.56M | 2.38M | 2.14M | 1.99M | 1.86M | 1.71M | 1.67M | 1.60M | 1.48M | 1.43M |
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
SHELTON, CT / ACCESSWIRE / November 28, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the Single-Ascending Dose part of the...
NanoViricides continues to progress antiviral drug candidate NV-CoV-2 in 3Q
NanoViricides (NYSE-A:NNVC) said it exited the third quarter with enough cash on hand to progress clinical trials involving its lead drug candidate NV-CoV-2 for SARS-CoV-2 which causes COVID. NV-CoV-2 is currently being evaluated in Phase 1a/1b human trials in India...
NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
SHELTON, CT / ACCESSWIRE / November 15, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending September 30, 2023 with the Securities and Exchange...
NanoViricides drug candidate found to be ‘highly effective' for MPox and Smallpox in animal trial
NanoViricides (NYSE-A:NNVC) has announced that its broad-spectrum antiviral drug candidate NV-387 in development for MPox and Smallpox was shown to be “highly effective” for these indications in an animal model. During the trial, animals treated with NV-387 matched the 14-day...
Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
SHELTON, CT / ACCESSWIRE / November 14, 2023 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reports that its broad-spectrum antiviral drug candidate, NV-387 was highly...
NanoViricides updates investors on Phase 1a/1b trial of antiviral drug candidate for coronavirus
NanoViricides (NYSE-A:NNVC) said it has sufficient funds to complete its ongoing Phase 1a/1b clinical trial of its lead drug candidate NV-CoV-2 based on its “nanoviricle” active pharmaceutical ingredient NV-387 for coronavirus. The company said NV-387 was “highly active” when tested...
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
SHELTON, CT / ACCESSWIRE / October 16, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2023 with the Securities and Exchange Commission...
NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
SHELTON, CT / ACCESSWIRE / October 12, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at the Partnership Opportunities in Drug Delivery (PODD) Conference in...
NanoViricides reports progress in Phase 1a/1b human clinical trial of NV-CoV-2 broad-spectrum antiviral drug
NanoViricides (NYSE-A:NNVC) has reported that the Phase 1a/1b human clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing successfully. According to the company's Indian collaborator and drug sponsor, Karveer Meditech, about 26 out of the target of 36 healthy...
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
SHELTON, CT / ACCESSWIRE / August 21, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the Phase 1a/1b Human Clinical Trial...
Source: https://incomestatements.info
Category: Stock Reports